Cargando…
Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis
BACKGROUND: Multiple sclerosis is the most common demyelinating disease of the central nervous system with serious social and economic burden. Siponimod is a sphingosine-1-phosphate receptor agonist, and clinical trials in the past decade have shown good prospects for the treatment of multiple scler...
Autores principales: | Song, Yumeng, Lao, Yongfeng, Liang, Fuxiang, Li, Jing, Jia, Bibo, Wang, Zixuan, Hui, Xu, Lu, Zhenxing, Zhou, Biao, Luo, Wei, Song, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716697/ https://www.ncbi.nlm.nih.gov/pubmed/31441835 http://dx.doi.org/10.1097/MD.0000000000015415 |
Ejemplares similares
-
Effect of alcohol intake on the development of mild cognitive impairment into dementia: A protocol for systematic review and dose–response meta-analysis
por: Yao, Lihe, et al.
Publicado: (2020) -
Siponimod for multiple sclerosis
Publicado: (2021) -
Empathy and theory of mind in multiple sclerosis: A protocol for systematic review and meta-analysis
por: Lin, XiaoGuang, et al.
Publicado: (2020) -
Efficacy and safety of SQJZ herbal mixtures on nonmotor symptoms in Parkinson disease patients: Protocol for a randomized, double-blind, placebo-controlled trial
por: Shi, Jing, et al.
Publicado: (2017) -
Prospects of siponimod in secondary progressive multiple
sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)